TrialClinical cancer research : an official journal of the American Association for Cancer Research2022

BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma.

Janice M Mehnert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.